These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 29596984)

  • 1. Cost Effectiveness of Biomarker Tests for Irritable Bowel Syndrome With Diarrhea: A Framework for Payers.
    Almario CV; Noah BD; Jusufagic A; Lew D; Spiegel BMR
    Clin Gastroenterol Hepatol; 2018 Sep; 16(9):1434-1441.e21. PubMed ID: 29596984
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SeHCAT [tauroselcholic (selenium-75) acid] for the investigation of bile acid malabsorption and measurement of bile acid pool loss: a systematic review and cost-effectiveness analysis.
    Riemsma R; Al M; Corro Ramos I; Deshpande SN; Armstrong N; Lee YC; Ryder S; Noake C; Krol M; Oppe M; Kleijnen J; Severens H
    Health Technol Assess; 2013 Dec; 17(61):1-236. PubMed ID: 24351663
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Predictive Model to Estimate Cost Savings of a Novel Diagnostic Blood Panel for Diagnosis of Diarrhea-predominant Irritable Bowel Syndrome.
    Pimentel M; Purdy C; Magar R; Rezaie A
    Clin Ther; 2016 Jul; 38(7):1638-1652.e9. PubMed ID: 27261204
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multi-gene Pharmacogenomic Testing That Includes Decision-Support Tools to Guide Medication Selection for Major Depression: A Health Technology Assessment.
    Ontario Health (Quality)
    Ont Health Technol Assess Ser; 2021; 21(13):1-214. PubMed ID: 34484487
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Testing for celiac sprue in irritable bowel syndrome with predominant diarrhea: a cost-effectiveness analysis.
    Spiegel BM; DeRosa VP; Gralnek IM; Wang V; Dulai GS
    Gastroenterology; 2004 Jun; 126(7):1721-32. PubMed ID: 15188167
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapist telephone-delivered CBT and web-based CBT compared with treatment as usual in refractory irritable bowel syndrome: the ACTIB three-arm RCT.
    Everitt H; Landau S; Little P; Bishop FL; O'Reilly G; Sibelli A; Holland R; Hughes S; Windgassen S; McCrone P; Goldsmith K; Coleman N; Logan R; Chalder T; Moss-Morris R
    Health Technol Assess; 2019 Apr; 23(17):1-154. PubMed ID: 31042143
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Value-based Pricing for Rifaximin Increases Access of Patients With Irritable Bowel Syndrome With Diarrhea to Therapy.
    Shah ED; Saini SD; Chey WD
    Clin Gastroenterol Hepatol; 2019 Dec; 17(13):2687-2695.e11. PubMed ID: 30831219
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparing Costs and Outcomes of Treatments for Irritable Bowel Syndrome With Diarrhea: Cost-Benefit Analysis.
    Shah ED; Salwen-Deremer JK; Gibson PR; Muir JG; Eswaran S; Chey WD
    Clin Gastroenterol Hepatol; 2022 Jan; 20(1):136-144.e31. PubMed ID: 33010413
    [TBL] [Abstract][Full Text] [Related]  

  • 9. AGA Technical Review on the Evaluation of Functional Diarrhea and Diarrhea-Predominant Irritable Bowel Syndrome in Adults (IBS-D).
    Carrasco-Labra A; Lytvyn L; Falck-Ytter Y; Surawicz CM; Chey WD
    Gastroenterology; 2019 Sep; 157(3):859-880. PubMed ID: 31351880
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of acupuncture for irritable bowel syndrome: findings from an economic evaluation conducted alongside a pragmatic randomised controlled trial in primary care.
    Stamuli E; Bloor K; MacPherson H; Tilbrook H; Stuardi T; Brabyn S; Torgerson D
    BMC Gastroenterol; 2012 Oct; 12():149. PubMed ID: 23095351
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased expression of brain-derived neurotrophic factor is correlated with visceral hypersensitivity in patients with diarrhea-predominant irritable bowel syndrome.
    Zhang Y; Qin G; Liu DR; Wang Y; Yao SK
    World J Gastroenterol; 2019 Jan; 25(2):269-281. PubMed ID: 30670915
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeted screening for Coeliac Disease among irritable bowel syndrome patients: analysis of cost-effectiveness and value of information.
    Mohseninejad L; Feenstra T; van der Horst HE; Woutersen-Koch H; Buskens E
    Eur J Health Econ; 2013 Dec; 14(6):947-57. PubMed ID: 23179163
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patients with irritable bowel syndrome-diarrhea have lower disease-specific quality of life than irritable bowel syndrome-constipation.
    Singh P; Staller K; Barshop K; Dai E; Newman J; Yoon S; Castel S; Kuo B
    World J Gastroenterol; 2015 Jul; 21(26):8103-9. PubMed ID: 26185382
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Economic Burden of Irritable Bowel Syndrome with Diarrhea: Retrospective Analysis of a U.S. Commercially Insured Population.
    Buono JL; Mathur K; Averitt AJ; Andrae DA
    J Manag Care Spec Pharm; 2017 Apr; 23(4):453-460. PubMed ID: 28345443
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Subtypes of irritable bowel syndrome on Rome III criteria: a multicenter study.
    Yao X; Yang YS; Cui LH; Zhao KB; Zhang ZH; Peng LH; Guo X; Sun G; Shang J; Wang WF; Feng J; Huang Q
    J Gastroenterol Hepatol; 2012 Apr; 27(4):760-5. PubMed ID: 21929652
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased intestinal mucosal leptin levels in patients with diarrhea-predominant irritable bowel syndrome.
    Liu DR; Xu XJ; Yao SK
    World J Gastroenterol; 2018 Jan; 24(1):46-57. PubMed ID: 29358881
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Economic burden of inadequate symptom control among US commercially insured patients with irritable bowel syndrome with diarrhea.
    Buono JL; Mathur K; Averitt AJ; Andrae DA
    J Med Econ; 2017 Apr; 20(4):353-362. PubMed ID: 27919177
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Diagnosis of Irritable Bowel Syndrome Using Rome IV Criteria and Limited Investigations is Durable in Secondary Care.
    Khasawneh M; Craig OF; Gracie DJ; Black CJ; Ford AC
    Clin Gastroenterol Hepatol; 2023 Dec; 21(13):3397-3404.e1. PubMed ID: 37302448
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Economic evaluation of tegaserod vs. placebo in the treatment of patients with irritable bowel syndrome: an analysis of the TENOR study.
    Bracco A; Jönsson B; Ricci JF; Drummond M; Nyhlin H
    Value Health; 2007; 10(4):238-46. PubMed ID: 17645678
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Price Is Right: Exploring Prescription Drug Coverage Barriers for Irritable Bowel Syndrome Using Threshold Pricing Analysis.
    Shah ED; Chang L; Lembo A; Staller K; Curley MA; Chey WD
    Dig Dis Sci; 2021 Dec; 66(12):4140-4148. PubMed ID: 33433804
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.